Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

LOREA : ANALYSIS OF THE EFFECTIVENESS AND SAFETY OF LORLATINIB IN UNTREATED ALK-POSITIVE NSCLC PATIENTS IN A FRENCH NON INTERVENTIONAL STUDY

NCT06487078 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT06487078
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06487078 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
LOREA : ANALYSIS OF THE EFFECTIVENESS AND SAFETY OF LORLATINIB IN UNTREATED ALK-POSITIVE NSCLC PATIENTS IN A FRENCH NON INTERVENTIONAL STUDY
Lead sponsor
Pfizer
Phase
Not applicable
Overall status
Recruiting
Start date
January 20, 2025
Completion date
November 30, 2028
Enrollment
90 (estimated)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

alk+ non-small-cell lung carcinoma